Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Gleevec Stories

2013-12-08 20:20:38

- ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus Gleevec(1) EAST HANOVER, N.J., Dec. 8, 2013 /PRNewswire/ -- Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna(®) (nilotinib) compared to Gleevec(®) (imatinib mesylate) tablets* at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient...

2013-09-23 23:04:49

Reportbuyer.com just published a new market research report: PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022. London (PRWEB) September 23, 2013 PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022”. Chronic myeloid leukemia...

2013-06-05 08:27:53

ANN ARBOR, Mich., June 5, 2013 /PRNewswire-USNewswire/ -- Two physician-scientists whose research transformed chronic myeloid leukemia (CML) from a routinely fatal to a manageable condition will share the 2013 Taubman Prize for Excellence in Translational Medical Science. The $100,000 prize is given by the A. Alfred Taubman Medical Research Institute, based at the University of Michigan Medical School. This year's recipients are Brian Druker, M.D., of Oregon Health & Science University,...

2013-04-16 12:23:10

ALBANY, N.Y., April 16, 2013 /PRNewswire-USNewswire/ -- Three physician scientists whose landmark research helped transform the treatment of cancer are the recipients of the prestigious Albany Medical Center Prize in Medicine and Biomedical Research, to be officially awarded May 17. The $500,000 award, given to those who have altered the course of medical research, is one of the largest prizes in medicine and science in the United States. This year, the prize will recognize...

2012-12-10 16:24:12

EAST HANOVER, N.J., Dec. 10, 2012 /PRNewswire/ -- The latest results from two Phase III clinical trials further establish the benefits of Tasigna(®) (nilotinib) compared to Gleevec(®) (imatinib mesylate) tablets* in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in newly diagnosed patients and in those with residual disease who switched to Tasigna after long-term treatment with Gleevec. Findings from both studies were presented in oral sessions...

2012-11-28 00:22:09

EAST HANOVER, N.J., Nov. 28, 2012 /PRNewswire/ -- Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases. The American Society of Hematology (ASH) annual meeting in Atlanta, held December 8-11, will feature significant data across...

2012-04-25 02:32:34

GAITHERSBURG, Md., April 25, 2012 /PRNewswire/ -- Zyngenia, Inc., a biopharmaceutical company developing Zybodies(TM), next-generation multi-specific antibody-based drugs in oncology and immunology, announced today that it has appointed David Parkinson, M.D. as a member of its Board of Directors and head of its Clinical Advisory Board. Dr. Parkinson will also serve as Interim Chief Medical Officer (CMO). "Since our start in September 2009, we at Zyngenia have validated our technology...

2012-02-13 12:00:00

Big Mountain Drugs, a licensed Canadian online pharmacy, is responding to the recent medication shortage by offering $25.00 off any cancer therapy order over $100.00. With coupon code feb25, patients, their caregivers, and hospitals can save when they buy cancer medications such as generic Gleevec or Tarceva. Vancouver, BC (PRWEB) February 13, 2012 Big Mountain Drugs, a leading Canadian online pharmacy, has partnered with BreastCancerCare.us to release a new coupon specifically for cancer...

2012-02-01 00:26:00

EAST HANOVER, N.J., Feb. 1, 2012 /PRNewswire/ -- Novartis announced today that following a priority review, the US Food and Drug Administration (FDA) has approved an update to the Gleevec(®) (imatinib mesylate)[*] tablets label to recommend 36 months of treatment after surgery for adult patients with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) who met the risk of recurrence inclusion criteria of the pivotal trial. This treatment regimen...

2012-01-31 17:14:00

Confirmatory trials show significantly prolonged survival in patients; drug granted regular approval SILVER SPRING, Md., Jan. 31, 2012 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today's action also highlights an increase in overall patient survival when the drug is taken for 36 months rather than the...